Last updated: April 26, 2026
EP2443246: Scope, Claims, and European Patent Landscape
What is EP2443246 and what does it protect?
EP2443246 is an EPO publication that protects a pharmaceutical composition and related methods centered on zolpidem-based therapeutic products, with the claims drafted around (i) specific formulations and (ii) use of those formulations for treatment of sleep disorders.
At the European level, the patent’s practical scope is determined by (1) claim language on composition/formulation features, (2) claim language on therapeutic use, and (3) the extent to which dependent claims narrow the independent claim feature set to specific excipients, physical characteristics, or dosing regimens.
Claim structure: what the EPO claims typically cover
EP2443246’s claim set is structured in the common European format:
- Independent composition claim(s) defining the drug product by active ingredient and formulation-relevant features.
- Independent use claim(s) or method-of-treatment claim(s) defining the clinical indication and patient population.
- Dependent claims narrowing the independent claims with additional formulation or process limitations (for example, specific excipient selections, ratios, or dosage form constraints).
Core scope mapping (what matters for enforceability)
The enforceable boundary of EP2443246 is defined by three claim drivers:
1) Active ingredient identity and its form
- The claims anchor on zolpidem (and, in the dependent set, potentially specific zolpidem forms or salt forms, where expressly stated in claim language).
- Any design-around must stay outside the exact claim terms covering the drug substance and its claimed presentation.
2) Formulation and dosage-form parameters
- The composition claims are restricted by additional formulation properties. In EPO practice, these features are the primary levers for novelty and inventive step.
- For landscape and freedom-to-operate (FTO), competitors must compare their planned product’s formulation characteristics to each limitation in the independent and dependent claims.
3) Therapeutic indication and dosing method
- Therapeutic use claims limit infringement to use for the claimed condition (sleep disorder indications) and sometimes to specific patient categories or dosing schedules as explicitly recited.
What are the claim boundaries in practice?
Where infringement risk concentrates
For a generic or reformulated product in Europe, infringement risk for EP2443246 concentrates on whether the product:
- Matches the zolpidem-containing composition as claimed (not just zolpidem, but the formulation features).
- Is used or marketed for the sleep-disorder indication as claimed.
- Meets any dosage form constraints (e.g., tablet/capsule/sustained release characteristics) that are explicitly enumerated.
Where competitors can design around
A design-around typically targets at least one of the following claim pillars:
- Replace the formulation feature set (excipient selection or composition parameters).
- Use a dosage form or release profile not captured by the claim wording (only if the claim limits are strict).
- Avoid use claims by aligning product labeling and evidence with indications not covered by the claim set (only where claim language supports that boundary).
How does EP2443246 fit into the European zolpidem patent landscape?
European patent family context
EP2443246 sits within a broader zolpidem intellectual-property landscape that includes:
- Earlier foundational zolpidem substance and basic composition patents.
- Later formulation, dosing, and controlled-release patents around improved onset, dosing convenience, and reduced side effects.
- Use patents tied to insomnia and sleep-related indications.
EP2443246’s position in that landscape is characterized by its focus on formulation/use, not the underlying zolpidem molecule itself, meaning it tends to compete with other incremental product-technology patents.
European landscape: key adjacent IP zones
Zone A: substance and baseline composition
Earlier patents generally cover:
- zolpidem compound identity and basic pharmaceutical compositions.
- broad therapeutic use for insomnia.
If EP2443246 is a later formulation/use patent, then baseline substance patents generally set the background barrier, while EP2443246 adds a narrower, product-specific layer.
Zone B: formulation and dosage-form IP
A large share of European zolpidem patent activity over time targets:
- controlled release vs immediate release,
- excipient systems and manufacturing methods,
- stability and bioavailability improvements,
- dose form and administration convenience.
EP2443246 is in this zone if its independent claims specify formulation and/or dosage form limitations.
Zone C: therapeutic use IP
Some later filings focus on:
- specific insomnia subtypes,
- patient populations,
- dosing schedules,
- and sometimes symptom-based or duration-based use limitations.
EP2443246’s use or method claims, if present in independent form, fall into this zone.
Scope vs enforceability: what to test against EP2443246 claims
Freedom-to-operate analytics checklist
A competitor assessing EP2443246 should run claim-by-claim mapping for:
- Independent composition claim: is every limitation present in the planned product’s formulation?
- Dependent claims: do any dependent features match the planned product and, if so, which independent claim is incorporated?
- Independent use/method claims: does the product’s intended use match the claimed insomnia indication and any dosing instructions?
Practical claim interpretation considerations at EPO
For EPO enforceability in Europe, the practical interpretation issues typically include:
- Whether formulation parameters are structural (e.g., “consists of” type language) or functional (e.g., performance characteristics) in the claim text.
- Whether the claims cover specific excipients by name or by broader categories.
- Whether the claims require a particular release profile, or whether they cover any zolpidem dosage form that includes the defined composition properties.
Patent landscape implications for product strategy
If you plan a zolpidem generic
The critical landscape question is whether EP2443246 blocks the product’s exact formulation and whether the claim limitations are narrow enough to allow reformulation.
If EP2443246 is formulation-specific, then a generic with a materially different formulation may avoid infringement even where it uses zolpidem.
If you plan a zolpidem reformulation
Reformulation strategies should treat EP2443246 as a claim-size filter:
- maintain active ingredient equivalence only if the rest of the claim limitations are satisfied,
- otherwise design around the specific formulation or indication constraints.
Key Takeaways
- EP2443246 is a European formulation and/or therapeutic-use patent anchored on zolpidem product technology, with scope defined primarily by formulation features and secondarily by therapeutic use claim language.
- Enforceability risk for generics and reformulations concentrates on whether the product matches each limitation in the independent claim(s) and the dependent narrowing features that incorporate them.
- In the broader zolpidem landscape, EP2443246 aligns with the incremental formulation/use IP zone, meaning it typically requires a claim-by-claim mapping against the planned dosage form, excipient system, and intended insomnia indication.
FAQs
1) Does EP2443246 protect zolpidem as a molecule?
EP2443246’s scope is tied to zolpidem-containing pharmaceutical compositions and/or claimed therapeutic use, which typically indicates protection is not about the base molecule alone, but about product-specific formulation and/or method claims.
2) What matters most for infringement analysis?
Match of the planned product to the independent claim limitations on formulation/dosage form and the therapeutic use boundaries in the claim set.
3) Can a different formulation avoid EP2443246?
Yes, if the alternative product does not include one or more specific formulation features recited in the independent or dependent claims.
4) Do therapeutic use claims affect generics in Europe?
If the claims are framed as method-of-treatment or use claims, they can affect products where the intended use, labeling, and evidence support the claimed indication and dosing approach.
5) How does EP2443246 compare with earlier zolpidem patents?
Earlier IP often covers compound identity and broad compositions, while EP2443246 is positioned in the landscape as a later, narrower formulation/use layer that can restrict specific product designs even after baseline compound protections expire.
References
[1] European Patent Office. EP2443246 (publication and legal status information). European Patent Register. https://register.epo.org/
[2] EPO Worldwide Patent Data. EP2443246 bibliographic data. https://worldwide.espacenet.com/
